SIBN — SI-BONE, Inc.

SI-BONE Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Worldwide revenue reached $56 million, a 15.2% increase year-over-year; U.S. revenue was $53.2 million, up 14.7%.
• Procedure Volume: U.S. procedure volume rose nearly 15%, with a 9% sequential increase, marking the strongest second-quarter growth in years.
• International Revenue: Increased by 25.9% to $2.8 million, driven by demand for the TORQ and TNT products.
• Adjusted EBITDA: Improved by 178% to $2.8 million, with an adjusted EBITDA margin of approximately 5.1%.
• Net Loss: Narrowed to $4.1 million ($0.09 per diluted share) from a loss of $6.2 million ($0.14 per diluted share) in the prior year.
• Cash Position: Ended the quarter with $145.9 million in cash and equivalents, reflecting positive cash flow from operations.

2. Strategic Updates and Business Highlights:

• Product Development: Submitted a 510(k) application for a new breakthrough device aimed at complex spine procedures, with a phased commercial launch expected in Q4 2026.
• Market Expansion: Continued to grow the physician base, with a 19% increase in unique physicians performing procedures.
• Reimbursement Improvements: Anticipated changes from CMS could enhance reimbursement rates for SI joint fusion procedures, potentially increasing hospital payments by up to $50,000.
• Commercial Strategy: Expanded U.S. field capacity with plans to increase territory managers from 93 to nearly 100 by year-end to support new product launches.

3. Forward Guidance and Outlook:

• Revenue Guidance: Raised the low end of 2026 revenue guidance to $231-$233 million (15%-16% growth), up from the previous range of $230-$233 million.
• Operating Expenses: Expected to increase by approximately 12% for the full year, with a maintained gross margin guidance of 79%.
• Long-term Growth: Anticipated continued revenue growth and profitability improvement into 2027, driven by new product adoption and favorable reimbursement changes.

4. Bad News, Challenges, or Points of Concern:

• Deceleration in Growth: The guidance for the second half of 2026 implies a potential deceleration in U.S. revenue growth compared to the first half, raising concerns about market penetration and competition.
• Utilization Trends: Despite a growing physician base, utilization rates have not significantly increased, which could limit revenue growth if not addressed.
• Market Risks: Ongoing economic pressures and payer environment challenges could impact procedure volumes and reimbursement rates.

5. Notable Q&A Insights:

• Market Dynamics: Management expressed confidence in the strong physician base and procedural demand, but acknowledged the need for a cautious approach to guidance due to potential seasonality and timing of reimbursement impacts.
• Product Launch Expectations: The new breakthrough device is expected to leverage existing relationships with physicians, potentially accelerating adoption and revenue growth.
• Smith+Nephew Partnership: The collaboration is progressing well, with expectations for increased adoption of SI-BONE products in trauma centers, although full ramp-up may take time.
• Future Investments: Management indicated a commitment to R&D spending to support long-term growth, focusing on organic growth rather than M&A.

Overall, SI-BONE's Q2 2026 results reflect strong performance and strategic positioning for future growth, although challenges related to market dynamics and utilization rates remain.